Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O 6 -methylguanine DNA methyltransferase promoter methylation via c-Myc signaling

An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β

(2012) Katsuyoshi Miyashita et al.   Anti-Cancer Agents in Medicinal Chemistry

A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma

(2011) S. Torres et al.   MOLECULAR CANCER THERAPEUTICS

In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy

(2010) Nathalie Wauthoz et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

The Correlation between Promoter Methylation Status and the Expression Level of O6-Methylguanine-DNA Methyltransferase in Recurrent Glioma

(2010) Tomohide Suzuki et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma

(2009) V Bilim et al.   BRITISH JOURNAL OF CANCER

Potential Therapeutic Effect of Glycogen Synthase Kinase 3  Inhibition against Human Glioblastoma

(2009) K. Miyashita et al.   CLINICAL CANCER RESEARCH

Glycogen Synthase Kinase-3 Inhibition Induces Glioma Cell Death through c-MYC, Nuclear Factor- B, and Glucose Regulation

(2008) S. Kotliarova et al.   CANCER RESEARCH